Business segment information (Tables)

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Schedule of Net Sales by SBU Reporting Segment

The table below presents net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE^® and Versashield™ in our Biologics segment.

	Three Months Ended June 30,
(U.S. Dollars, in thousands)	2015		2014		Reported Increase (Decrease)			Constant Currency Increase (Decrease)
BioStim	$	40,703	$	39,513		3	%		3	%
Biologics		15,274		13,853		10	%		10	%
Extremity Fixation		25,594		27,303		(6	)%		12	%
Spine Fixation		19,383		20,316		(5	)%		(4	)%
Total Net Sales	$	100,954	$	100,985		(0	)%		5	%

	Six Months Ended June 30,
(U.S. Dollars, in thousands)	2015		2014		Reported Increase (Decrease)			Constant Currency Increase (Decrease)
BioStim	$	78,403	$	76,650		2	%		2	%
Biologics		29,235		26,863		9	%		9	%
Extremity Fixation		47,409		54,369		(13	)%		2	%
Spine Fixation		35,669		43,117		(17	)%		(17	)%
Total Net Sales	$	190,716	$	200,999		(5	)%		(1	)%

Summary of Net Margin by SBU Reporting Segment

The table below presents net margin by SBU reporting segment:

	Three Months Ended June 30,						Six Months Ended June 30,
(U.S. Dollars, in thousands)	2015			2014			2015			2014
Net margin:
BioStim	$	16,787		$	17,706		$	30,800		$	32,726
Biologics		7,285			6,496			13,229			12,997
Extremity Fixation		9,149			6,656			16,165			13,590
Spine Fixation		3,173			3,130			2,644			7,189
Corporate		(296	)		(430	)		(602	)		(874	)
Total net margin		36,098			33,558			62,236			65,628
General and administrative		22,506			18,214			44,075			36,074
Research and development		6,451			6,313			12,296			12,246
Restatements and related costs		2,213			2,327			8,129			10,633
Operating income (loss)	$	4,928		$	6,704		$	(2,264	)	$	6,675